On theoretical grounds, such combination regimens involving both ICD inducers and cDC1-targeted immune checkpoint inhibitors could be used to sensitize cancer patients to subsequent blockade of the PD-1/PD-L1 interaction or other T cell-targeted immunotherapies. The gene discussed is PDCD1; the disease is cancer.